|
Name |
Pyranonigrin A
|
Molecular Formula | C10H9NO5 | |
IUPAC Name* |
(7R)-3,7-dihydroxy-2-[(E)-prop-1-enyl]-6,7-dihydropyrano[2,3-c]pyrrole-4,5-dione
|
|
SMILES |
C/C=C/C1=C(C(=O)C2=C(O1)[C@H](NC2=O)O)O
|
|
InChI |
InChI=1S/C10H9NO5/c1-2-3-4-6(12)7(13)5-8(16-4)10(15)11-9(5)14/h2-3,10,12,15H,1H3,(H,11,14)/b3-2+/t10-/m1/s1
|
|
InChIKey |
OALBJWDVDNROSF-VMZHVLLKSA-N
|
|
Synonyms |
Pyranonigrin A; 773855-65-5; Pyrano[3,2-b]pyrrole-3,7-dione, 1,2-dihydro-2,6-dihydroxy-5-(1E)-1-propenyl-, (2R)- (9CI); (7R)-6,7-dihydro-3,7-dihydroxy-2-(1E)-1-propen-1-yl-pyrano[2,3-c]pyrrole-4,5-dione; 7-hydroxy Pyranonigrin S; CHEBI:133779; DTXSID501017485; ZINC95909040; HY-126604; CS-0105857; (7R)-3,7-dihydroxy-2-[(1E)-prop-1-en-1-yl]-6,7-dihydropyrano[2,3-c]pyrrole-4,5-dione; (7R)-3,7-dihydroxy-2-[(E)-prop-1-enyl]-6,7-dihydropyrano[2,3-c]pyrrole-4,5-dione
|
|
CAS | 773855-65-5 | |
PubChem CID | 16756786 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 223.18 | ALogp: | -0.5 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 95.9 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.644 |
Caco-2 Permeability: | -4.921 | MDCK Permeability: | 0.00001270 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.049 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.036 |
Blood-Brain-Barrier Penetration (BBB): | 0.029 | Plasma Protein Binding (PPB): | 86.49% |
Volume Distribution (VD): | 0.854 | Fu: | 11.90% |
CYP1A2-inhibitor: | 0.362 | CYP1A2-substrate: | 0.769 |
CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.054 |
CYP2C9-inhibitor: | 0.167 | CYP2C9-substrate: | 0.787 |
CYP2D6-inhibitor: | 0.121 | CYP2D6-substrate: | 0.293 |
CYP3A4-inhibitor: | 0.049 | CYP3A4-substrate: | 0.046 |
Clearance (CL): | 5.254 | Half-life (T1/2): | 0.924 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.915 |
Drug-inuced Liver Injury (DILI): | 0.991 | AMES Toxicity: | 0.079 |
Rat Oral Acute Toxicity: | 0.624 | Maximum Recommended Daily Dose: | 0.209 |
Skin Sensitization: | 0.792 | Carcinogencity: | 0.871 |
Eye Corrosion: | 0.053 | Eye Irritation: | 0.55 |
Respiratory Toxicity: | 0.213 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002385 | 0.585 | D03TGJ | 0.198 | ||||
ENC001753 | 0.328 | D0YX4S | 0.194 | ||||
ENC006074 | 0.279 | D0YH0N | 0.193 | ||||
ENC004404 | 0.279 | D03KXY | 0.189 | ||||
ENC001843 | 0.263 | D0CL9S | 0.187 | ||||
ENC004924 | 0.262 | D0R2KF | 0.175 | ||||
ENC004982 | 0.261 | D09PZO | 0.171 | ||||
ENC003039 | 0.261 | D0TS1Z | 0.171 | ||||
ENC003951 | 0.260 | D0K8KX | 0.170 | ||||
ENC002929 | 0.258 | D07MGA | 0.169 |